Targeting βiii-Tubulin and the roots of science: An interview with Richard F. Ludueña

Targeting βiii-Tubulin and the roots of science: An interview with Richard F. Ludueña Professor Emeritus Richard F. Ludueña discusses his novel theoretical framework for cancer chemotherapy, utilising CRISPR-Cas9 to target specific tubulin isotypes. He also explores his current research into the historical intersection of science and religion in the ancient Mesopotamian centres of Harran and Edessa.